Feb 23, 2021
Based on the SOLOIST-WHF and SCORED trials, there is now evidence to treat patients with HFpEF with SGLT2 inhibitors and to start treatment early in HFrEF and HFpEF. In this interview, L. Kristin Newby, MD, MHS, FACC; Deepak L. Bhatt MD, FACC; and Shashank Sinha, MD, discuss the expanding biology of SGLT2. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.